General Updates

November 04, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, Corporate Relationship Department Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Bandra (E) Dalal Street Mumbai – 400 051 Mumbai – 400 001 Symbol: LALPATHLAB Scrip Code: 539524 Sub: Outcome of Board Meeting held on November 04, 2026 Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“the Listing Regulations”) Dear Sir/ Madam, Please take note that the Board of Directors in their meeting held today i.e. November 04, 2026, inter-alia considered, noted and approved the following(s): Financial Results 1. Un-audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and Half Year ended September 30, 2026. A signed copy of the above Financial Results (Standalone & Consolidated) along with Limited Review Report issued by Statutory Auditors thereon under Regulation 33 of the Listing Regulations is attached herewith as “Annexure- A”. Interim Dividend 2. Declaration of 2nd Interim Dividend of INR 5/- per equity share (@ 50% on a face value of INR 10/- each) for the financial year 2026-27. The record date for the purpose of payment of 2nd Interim Dividend shall be November 11, 2026. The 2nd Interim Dividend will be paid within 30 days of its declaration. Appointment of Director 3. Based on the recommendation of Nomination and Remuneration Committee, the Appointment of Ms. Vasuta Agarwal (DIN: 07480674) as an Additional Director designated as a Non- Executive Independent Director on the Board of the Company, for a term of three (3) consecutive years commencing from November 04, 2026, subject to approval of Members of the Company through postal ballot. Please also take note that Ms. Vasuta Agarwal is not debarred from holding the office of Director by virtue of any order of Securities and Exchange Board of India or any other such Authority. The disclosure(s) as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, as amended from time to time are enclosed herewith as “Annexure – B”. Further investment in Subsidiary Company 4. Further investment(s) of an amount upto INR 49.5 Crores in Dr. Lal PathLabs FZCO, (“LPL Dubai”), a Wholly Owned Subsidiary of the Company, in one or more tranches, for meeting its business and operational requirements, including making further investment in its subsidiary, Sunshine Healthcare Limited (“SHL”), Ghana. The disclosure(s) as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, as amended from time to time is enclosed herewith as “Annexure – C”. The Board Meeting commenced at 11:49 A.M. (IST) and concluded at 01:20 P.M. (IST). We request you to please take the same on record. Thanking You, Yours Faithfully, For Dr. Lal PathLabs Limited Vinay Gujral Company Secretary & Compliance Officer Encl.: As above AnnexAure- Deloitte CharteAcrecdo untants 7th FBluoiol1rd0 i ng Hask&iS nesLl LlPs Tower B DLCFy bCeirty Complex DLCFi Ptyh aIsIe Gurugr0a0m2� 122 Haryana, lndia Te+i91:12 647 9 2000 Fa+x91:12 4 2607192 INDEPENDEANUTD ITORR'ESV IEWR EPOROTN REVIEWO F INTERIUMN AUDITED CONSOUDATFEIDN ANCIRAELS ULTS TOT HEB OARDO FD IRECTOORFS DrL.A LP ATHLAUBMSI TED 1.Weh avree vitehwaeecc do mpaSntyaitnegom fUe nnatu dCiotnesdo lFiidnaaRtneecsdiu allt s of DrL. aPla thlaLbism it(e"dt Phaer eanntId"t s)su bsi(dtiPhaaerr iaeennsidt t s su bsidiaries togertehfeetrrao rs "e tdGh reo ufpot"rh)q e u aratnedr sixe nmdSoeendpt thes3m 0b2,e0 r2 6 ('tShtea tembeenistnu'gb) m,ib tytt hPeead r peunrts tuoa nrtteh qeu iorfeR meegnutl3 a3tion oft hSeE B(IL isOtbilnigga antDdii osncslR oesquurier Reemgeunltas2t)0i 1ao5san, ms e,n ded ("tLhies Rteignugl ations"). 2.ThiSst atewmheinicttsh,h r ee sponosfti hbPeia lrieMtnaytn 'asg eamneadnp tp rboyvt ehde PareBnota'orsfd Dirheacbste oeprnrs e,p airnae cdc orwdiatnthech ree cogannidtion measurpermienncltia dpioldwe insnt hIen dian ASctcaonu3dn4at rid"n IgFn itnearnicmi al Repor(t"iIAnnSg3d "4 "p)r,e scurnidSbeeercd t1 i3o3n oCfo mtphaAenc ite,s 2w0i1t3h read relervualInestss t uheedr eaunnoddt eharec rc oupnrtiinncgi plaecsc egipeIntnn eedadrin aadl ly icn omplwiiaRtnehcg eu l3a3ot fti hoLeni sRteignugl aOturireo snpso.n istsio eb xiplraietsys conclounts hiSeot na tebmaesonentod u rre view, 3. Wceo nduocutrree dv ioefw Stthaet eImnae cncto rwdiatnthchS eet andoanRr edv iew Engage(mSeRnEt)s "R2e4v1oi0fe I wn teFriinma nIcnifaolr mPaetrifoobnry m edt he IndepeAnuddeiontftto h re Einstsibutyethy de"I ,n stoifCt huatrteeA rcecdo unotfIa nndtisa (!CAAr Ie)v.oi fe wi nteriinmfo rfmiantainocmnia akcliio nnngqs uipisrrtiisme oasofPr,f ai rleyn t's persornenseplof nosfirin balnaecn iadac lc oumnattitanengra dsp playnianlgya tnoidtc haelr revpireowc eAdr uerveiissse.u w b stalneitssnisc a oltplheyaa nna udciotn duicantc ecdo rdance wiSttha ndoanAr uddsi stpiencgui nfdiSeeerdc t1i4o3n(o 1ft0 h)Ce o mpaAnci2te0,s1 a 3n d conseqduoeennsote tln ya bulse o tbot aasisnu rtahnawcetwe o ubledco maew aorfea ll signimfaitcttaehnrmatsit g bheit d enitanin fa iuedAdic tc.o rdweid nong oletyx ,p raenas usd it opinion. 4.ThSet ateimnecnlttuh rdeee ssou ftl htfeso lleonwtiintgl es: a)DrL.a l PaLtihmLitathPbeeasd r ,e nt company b)PalDliwaagln PorsitLviiacsmt ieat s eudb,s icdoimaprayn y c)DrLa.lP athNLeapbPasrl i Lviamtieat s eudb,s icdoimaprayn y d)DrL.aP la thBLaanbgsl PardieLvsiahmt ieat s eudb,s icdoimaprya ny e)DrL.aV le ntPurrieLvsia mtieat s eudb,s icdoimaprya ny f) NeuoTmeec hnoPlroigLviiaemtsie( t we,Adeu .gf2u 7s2,t0 2a6n)A ,s soCcoimaptaen y g)PathULnaibfPsir eirLvsia mtieat s eudb,s icdoimaprayn y h)CentrLaapbPasrt ihLv iamtieat s etde,p -sduobwsnic doimaprayn y i)APRL PaPtrihLvLaiabmtsie at s etde,p -sduobwsnic doimaprayn y j)ChanLraeb orPartioLvriaymt ieat s etde,p -sduobwsnic doimaprayn y k)ShahbaDzikaegrnCsoe sntPtirrcieL v iamtieats eudb,5 icdoimap(rawyn. yMe a.0yf1 .2, 0 26) I)DrL.aP la thFlZaCbaOs , s ubcsoimdpi(aawnr.yyJe u.n1fe2.2 , 0 26) m)SunsHheiancleat rGheh ,a( nwa. Aeu.gf0u.4s 2,t0 2a6s )t ep-sduobwsnic doimaprayn y n)DrL aPla thIlnadbosLm Le(Cdw .Aeu.gfu1.s9 t, 2s0t2e6p)- sduaob wsnic doimaprayn y RegOdff.iO cnele:n terCneantTtloeowrne,3ar 1l fls 3ot,oS re,n aBpaapMtaaitrE g.! phiRnosa(Wtdeo snMteu) m,b a011"'M34a,0h 0a rIansdhitar.a , DeloHiatstkSeie nLlsLl iPsr&s e giwsltthe rLeLidim aihbtaievldLii LntiPgyd entNiofM:iS. c.a8t7i3o7n Annexu8r'e OrL.a Pla tht.abLsi mited Stand.-hCtan$fhel oSwt atement (INIR.n mineixoeenµs,at s st ated) Veatrod atfei gufreers Year dtaotf ei glJforer<J Particulars thei;: urrepnettr leondd ed thup revipoeursl «J 30S eptemb2e0r2,6 ended se3p0t eemrrb 2025 (Unaudited) {Unaudited) Cash nforwosom p erataicntgi vlties Proffito trh pee riod J,456 2,750 Adjustmfeonrt:s T{IX expense 1,176 922 tntereisntc ome (321} (309) Rentianlc ofmreo i'mn vestn'leritproperty {17} (17) D!VidIenncdo fmroem a subsciodmipaaryn y (16) Negta ionns aloerf aviarl uaUIonnv ecsft m(eaFVTntPt Ls) (194) (145) NeGta ionn s aloefi nvestm{ennetls) (2) (Proflt)/Loss odni sdcoiafspr prdoo spaeplrl/ta yan,nt ed q uipment (net} 2 (2) Expensree cognIinrs eesdp oefect m plosyheaebr aes ceodm pensation 89 138 Finance costs 130 91 Depredaatnid;:;o rnno ,tlseaxtpleonns e 832 713 Provifsoilrom np airr."o_fet nrtar deece ivaabnldae dsv ances 140 9 Badd ebatnsd a dvanwcreisl otfefn 3 13 Operatptrnogfib tef orweo rkicnagp iatnadol t hecrh anges 5,278 4 , 1 6 3 Chan9iunw orkicnagp ital! Adjustmfoern( ti ncrea:se)/Idne1:, cpreeraastaeis nsge ts: (Increase)i/nDi encvreenatS!i!'o ries (113) (137) (Increase)/IDnte rcarrdeeeca esiev ables (331} (179) {I11crease)/Decrease in loans (3) (7) (Increase)i/nDoe tchreera sfiean sasn.ec::isa l (10) (26) (1ncraase)i/nDo ethcerre aesses uts {32) (38) AdjU9ttnfeonrt; lncrease/I(nod pencrartlenalgsl ea)b llltlos: Incroose/(dlehct rreop,:,daseye a) [Showing first 8,000 characters — download PDF for full document]